Compound ID | 3579
Lariocidin B
Class: Antimicrobial peptide
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-negative & Antimycobacterial |
| Mechanism of action: | Protein synthesis inhibitor. Binds to the16S ribosomal RNA and aminoacyl-tRNA to inhibit translocation and cause misreading |
| Target Pathogen: | Active against Acinetobacter baumannii and Mycobacterium smegmatis |
| Description: | Natural product from Paenibacillus sp. M2; shows efficacy in treating Acinetobacter baumannii in mouse neutropenic thigh infection model; a lasso peptide |
| Institute where first reported: | David Braley Centre for Antibiotics Discovery, McMaster University, Hamilton, Ontario, Canada |
| Year first mentioned: | 2025 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://www.nature.com/articles/s41586-025-08723-7 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.